Frazier Lifesciences Acquisition Corporation Unit
| 9.50 | +0.2299 | +2.48% | Vol 18.20K | 1Y Perf -5.47% |
| Nov 22nd, 2022 15:59 DELAYED |
| BID | 7.77 | ASK | 9.97 | ||
| Open | 10.00 | Previous Close | 9.27 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.00 | Earnings Rating | — | |
| Market Cap | 72.44M | Earnings Date | - | |
| Alpha | -0.00 | Standard Deviation | 0.02 | |
| Beta | -0.07 |
Today's Price Range 8.0710.80 | 52W Range 8.8710.61 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | - | ||
| 3 Months | - | ||
| 6 Months | - | ||
| 1 Year | -5.47% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -2.82 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -2.62 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -3.46 | |||
Return on invested Capital Q | -4.24 | |||
Return on invested Capital Y | 3.22 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.10 | ||||
| 0.10 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 18.20K |
| Shares Outstanding | 7.63K |
| Shares Float | 7.63M |
| Trades Count | 203 |
| Dollar Volume | 168.57K |
| Avg. Volume | 7.22K |
| Avg. Weekly Volume | 6.10K |
| Avg. Monthly Volume | 7.87K |
| Avg. Quarterly Volume | 7.70K |
Frazier Lifesciences Acquisition Corporation Unit (NASDAQ: FLACU) stock closed at 9.5 per share at the end of the most recent trading day (a 2.48% change compared to the prior day closing price) with a volume of 18.20K shares and market capitalization of 72.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Diversified Financial Services industry, Financial Services sector and employs 4 people. Frazier Lifesciences Acquisition Corporation Unit CEO is James N. Topper.
The one-year performance of Frazier Lifesciences Acquisition Corporation Unit stock is -5.47%, while year-to-date (YTD) performance is 0%. FLACU stock has a five-year performance of %. Its 52-week range is between 8.87 and 10.605, which gives FLACU stock a 52-week price range ratio of %
Frazier Lifesciences Acquisition Corporation Unit currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -2.62%, a ROC of -3.46% and a ROE of -2.82%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Frazier Lifesciences Acquisition Corporation Unit, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Frazier Lifesciences Acquisition Corporation Unit’s next earnings report date is -.
The consensus rating of Wall Street analysts for Frazier Lifesciences Acquisition Corporation Unit is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Frazier Lifesciences Acquisition Corporation Unit stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Frazier Lifesciences Acquisition Corporation Unit has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Frazier Lifesciences Acquisition Corporation Unit has a Sell technical analysis rating based on Technical Indicators (ADX : 18.09, ATR14 : 0.61, CCI20 : -102.48, Chaikin Money Flow : 0.10, MACD : -0.17, Money Flow Index : 55.67, ROC : -7.14, RSI : 41.09, STOCH (14,3) : 52.38, STOCH RSI : 0.40, UO : 50.07, Williams %R : -47.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Frazier Lifesciences Acquisition Corporation Unit in the last 12-months were:
Frazier Lifesciences Acquisition Corporation Unit
Frazier Lifesciences Acquisition Corp is a blank check company.
CEO: James N. Topper
Telephone: +1 206 621-7200
Address: 601 Union Street, Seattle 98101, WA, US
Number of employees: 4
